Allscripts Announces Third Quarter 2019 Results

  • Strong third quarter bookings of $236 million, up 19% year-over-year
  • GAAP EPS ($0.03); 6% year-over-year growth in non-GAAP diluted EPS to $0.17
  • Extended Allscripts Sunrise platform with Northwell Health through 2027
  • Repurchased $46 million of stock in the third quarter

CHICAGO–(BUSINESS WIRE)–Allscripts Healthcare Solutions, Inc. (Nasdaq: MDRX) (Allscripts) announced its financial results for the three and nine months ended September 30, 2019.

Third Quarter Financial Highlights

Bookings(1) were $236 million in the third quarter of 2019. This result compares with $198 million in the third quarter of 2018. Contract revenue backlog totaled $3.9 billion as of September 30, 2019.

Third quarter 2019 GAAP revenue was $444 million, up 3 percent year-over-year. Third quarter 2019 non-GAAP revenue totaled $445 million, up 1 percent year-over-year.

On a GAAP basis in the third quarter of 2019, total operating expenses were $172 million, or a 3 percent decrease year-over-year. Non-GAAP operating expenses totaled $148 million, or a 1 percent decrease year-over-year. Additionally, the company recorded $16 million of transaction, legal and other costs in the third quarter of 2019. This compares with $14 million of such costs in the third quarter of 2018.

GAAP net loss in the third quarter of 2019 totaled ($6) million compared with net loss of ($36) million in the third quarter of 2018. Non-GAAP net income in the third quarter of 2019 totaled $28 million compared with $29 million in the third quarter of 2018.

GAAP loss per share in the third quarter of 2019 was ($0.03), compared with loss per share of ($0.20) in the third quarter of 2018. Non-GAAP diluted earnings per share in the third quarter of 2019 were $0.17 compared with $0.16 in the third quarter of 2018.

Adjusted EBITDA totaled $74 million in the third quarter of 2019, compared with $78 million in the third quarter of 2018.

Stock repurchases totaled $46 million in the third quarter of 2019.

Our third quarter results show continued strength in new bookings, reflecting how our award-winning solutions resonate with both longtime clients as well as those new to Allscripts,” commented Paul M. Black, Chief Executive Officer of Allscripts. “We were proud to extend our Sunrise partnership with our largest client, Northwell Health, and we’re excited to jointly develop the next-generation electronic health record with Northwell. Looking ahead, we believe revenue growth will improve as we benefit from the strategic investments we’ve made and the platforms we’ve created across both our Provider and Veradigm businesses.”

2019 Financial Outlook(2)

Allscripts is revising the following expectations:

  • Full year 2019 non-GAAP earnings per share between $0.67 and $0.70, an increase at the midpoint from the prior outlook of between $0.65 and $0.70

Allscripts is reiterating the following expectations:

  • Full year 2019 bookings(1) between $1,050 million and $1,100 million
  • Fourth quarter 2019 non-GAAP revenue between $460 million and $470 million

Conference Call

Allscripts will conduct a conference call today, Monday, November 4th, 2019, at 4:30 PM Eastern Time to discuss its earnings release and other information. Participants may access the conference call via webcast at http://investor.allscripts.com. Participants also may access the conference call by dialing +1 (877) 269-7756 or +1 (201) 689-7817 (international) and requesting Conference ID # 13694490.

A replay of the call will be available approximately two hours after the conclusion of the call, for a period of four weeks, on the Allscripts Investor Relations website or by calling +1 (877) 660-6853 or +1 (201) 612-7415 – Conference ID # 13694490.

Supplemental and non-GAAP financial information is also available at http://investor.allscripts.com.

Footnotes

  1. Bookings have been determined on a continuing operations basis, excluding Netsmart, and reflect the value of executed contracts for software, hardware, client services, private cloud hosting services, outsourcing and other subscription-based services.
  2. In providing financial guidance, the company does not reconcile non-GAAP earnings per share and non-GAAP revenue guidance to the corresponding GAAP financial measures. Allscripts does not provide guidance for the various reconciling items since certain items that impact GAAP net income and GAAP revenue such as acquisition-related deferred revenue adjustments, acquisition-related amortization, asset impairment charges and transaction, legal and other costs, any of which may be significant, are either outside of its control and/or cannot be reasonably predicted. Please see the “Explanation of Non-GAAP Financial Measures” at the end of this press release for detailed information on calculating non-GAAP measures. For a reconciliation of other non-GAAP items, see the non-GAAP financial reconciliation tables in this release (Tables 4, 5, 6 and 7).

NOTE: All percentage changes described within this press release are calculated from full dollar amounts as illustrated in the accompanying financial statements and Allscripts Supplemental Financial Data Workbook, posted on the Investor Relations website. Rounding differences may occur when individually calculating percentages or totals from rounded amounts included within the press release body compared to full dollar amounts in the tables.

About Allscripts

Allscripts (Nasdaq: MDRX) is a leader in healthcare information technology solutions that advance clinical, financial and operational results. Our innovative solutions connect people, places and data across an Open, Connected Community of Health™. Connectivity empowers caregivers to make better decisions and deliver better care for healthier populations. To learn more, visit www.allscripts.com, Twitter, YouTube and It Takes A Community: The Allscripts Blog.

###

© 2019 Allscripts Healthcare, LLC and/or its affiliates. All Rights Reserved.

Allscripts, the Allscripts logo, and other Allscripts marks are trademarks of Allscripts Healthcare, LLC and/or its affiliates. All other products are trademarks of their respective holders, all rights reserved. Reference to these products is not intended to imply affiliation with or sponsorship of Allscripts Healthcare, LLC and/or its affiliates.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including the statements under “2019 Financial Outlook” and statements related to expected benefits of strategic partnerships and investments. These forward-looking statements are based on the current beliefs and expectations of Allscripts management, only speak as of the date that they are made and are subject to significant risks and uncertainties. Such statements can be identified by the use of words such as “future,” “anticipates,” “believes,” “estimates,” “expects,” “intends,” “plans,” “predicts,” “will,” “would,” “could,” “can,” “may,” and similar terms. Actual results could differ significantly from those set forth in the forward-looking statements and reported results should not be considered an indication of future performance. Certain factors that could cause Allscripts actual results to differ materially from those described in the forward-looking statements include, but are not limited to: the final outcome of the criminal and civil investigations by the DOJ involving Practice Fusion, including our ability to negotiate final settlement agreements with the DOJ and the terms of such agreements; potential additional investigations and proceedings from governmental entities or third parties other than the DOJ related to the same or similar conduct underlying the DOJ’s investigations into Practice Fusion’s business practices; the expected financial results of businesses acquired by us, including the EIS business, the NantHealth provider/patient solutions business, Practice Fusion and HealthGrid; the successful integration of businesses recently acquired by us; the anticipated and unanticipated expenses and liabilities related to the EIS business, the NantHealth provider/patient solutions business, Practice Fusion and HealthGrid, including the civil investigation by the U.S. Attorney’s Office involving our EIS business; security breaches resulting in unauthorized access to our or our clients’ computer systems or data, including denial-of-services, ransomware or other Internet-based attacks; Allscripts failure to compete successfully; consolidation in Allscripts industry; current and future laws, regulations and industry initiatives; increased government involvement in Allscripts industry; the failure of markets in which Allscripts operates to develop as quickly as expected; Allscripts or its customers’ failure to see the benefits of government programs; changes in interoperability or other regulatory standards; the effects of the realignment of Allscripts sales, services and support organizations; market acceptance of Allscripts products and services; the unpredictability of the sales and implementation cycles for Allscripts products and services; Allscripts ability to manage future growth; Allscripts ability to introduce new products and services; Allscripts ability to establish and maintain strategic relationships; risks related to the acquisition of new businesses or technologies; the performance of Allscripts products; Allscripts ability to protect its intellectual property rights; the outcome of legal proceedings involving Allscripts; Allscripts ability to hire, retain and motivate key personnel; performance by Allscripts content and service providers; liability for use of content; price reductions; Allscripts ability to license and integrate third party technologies; Allscripts ability to maintain or expand its business with existing customers; risks related to international operations; changes in tax rates or laws; business disruptions; Allscripts ability to maintain proper and effective internal controls; and asset and long-term investment impairment charges. Additional information about these and other risks, uncertainties, and factors affecting Allscripts business is contained in Allscripts filings with the Securities and Exchange Commission, including under the caption “Risk Factors” in the most recent Allscripts Annual Report on Form 10-K and subsequent Form 10-Qs. Allscripts does not undertake to update forward-looking statements to reflect changed assumptions, the impact of circumstances or events that may arise after the date of the forward-looking statements, or other changes in its business, financial condition or operating results over time.

Table 1
Allscripts Healthcare Solutions, Inc.
Condensed Consolidated Balance Sheets
(In millions)
(Unaudited)
 

September 30,

December 31,

2019

2018

ASSETS
Current assets:
Cash and cash equivalents

$129.3

$174.2

Restricted cash

9.4

10.6

Accounts receivable, net

426.6

465.3

Contract assets

65.5

66.4

Prepaid expenses and other current assets

142.8

142.5

Total current assets

773.6

859.0

Fixed assets, net

96.8

121.9

Software development costs, net

236.6

209.7

Intangible assets, net

398.0

431.1

Goodwill

1,387.1

1,373.7

Deferred taxes, net

5.0

5.0

Contract assets – long-term

101.9

71.9

Right-of-use assets – operating leases

103.5

0.0

Other assets

127.4

109.2

Total assets

$3,229.9

$3,181.5

 
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable

$101.7

$73.2

Accrued expenses

261.9

107.0

Accrued compensation and benefits

57.5

100.1

Income tax payable

0.0

29.6

Deferred revenue

373.1

466.8

Current maturities of long-term debt

358.6

20.1

Current operating lease liabilities

24.5

0.0

Current liabilities attributable to discontinued operations

0.0

0.9

Total current liabilities

1,177.3

797.7

Long-term debt

554.9

647.5

Deferred revenue

12.1

16.0

Deferred taxes, net

55.3

58.5

Long-term operating lease liabilities

100.1

0.0

Other liabilities

49.1

81.4

Total liabilities

1,948.8

1,601.1

Total Allscripts Healthcare Solutions, Inc.’s stockholders’ equity

1,281.1

1,551.1

Non-controlling interest

0.0

29.3

Total stockholders’ equity

1,281.1

1,580.4

Total liabilities and stockholders’ equity

$3,229.9

$3,181.5

Table 2
Allscripts Healthcare Solutions, Inc.
Condensed Consolidated Statements of Operations
(In millions, except per share amounts)
(Unaudited)
 

Three Months Ended September 30,

Nine Months Ended September 30,

2019

2018

2019

2018

Revenue:
Software delivery, support and maintenance

$284.4

$274.2

$844.9

$839.2

Client services

159.8

158.3

475.8

468.5

Total revenue

444.2

432.5

1,320.7

1,307.7

Cost of revenue:
Software delivery, support and maintenance

90.4

86.8

269.9

265.8

Client services

149.2

142.1

430.8

429.4

Amortization of software development and acquisition-related assets (a)

29.3

25.5

86.5

76.0

Total cost of revenue

268.9

254.4

787.2

771.2

Gross profit

175.3

178.1

533.5

536.5

Selling, general and administrative expenses

101.1

108.1

306.9

351.0

Research and development

63.9

63.0

191.6

202.3

Asset impairment charges

0.2

0.0

4.0

30.1

Amortization of intangible and acquisition-related assets

6.9

6.6

20.4

19.6

Income (loss) from operations

3.2

0.4

10.6

(66.5)

Interest expense and other, net (b)

(10.0)

(13.9)

(175.1)

(37.6)

Gain (loss) on sale of business, net

0.0

0.0

0.0

172.3

Recovery (impairment) on long-term investments

0.0

0.0

1.0

(15.5)

Equity in net income (loss) of unconsolidated investments

0.3

(0.4)

0.5

0.4

Income (loss) before income taxes

(6.5)

(13.9)

(163.0)

53.1

Income tax (provision) benefit

0.8

1.8

(0.6)

(5.8)

Income (loss) from continuing operations, net of tax

(5.7)

(12.1)

(163.6)

47.3

Income (loss) from discontinued operations

0.0

(13.8)

0.0

(32.9)

Income tax effect on discontinued operations

0.0

2.1

0.0

7.5

Income (loss) from discontinued operations, net of tax

0.0

(11.7)

0.0

(25.4)

Net income (loss)

(5.7)

(23.8)

(163.6)

21.9

Net (income) loss attributable to non-controlling interest

0.0

0.0

0.4

3.5

Accretion of redemption preference on redeemable convertible
non-controlling interest – discontinued operations

0.0

(12.1)

0.0

(36.4)

Net Income (loss) attributable to Allscripts Healthcare Solutions, Inc. stockholders

($5.7)

($35.9)

($163.2)

($11.0)

 
Income (loss) from continuing operations per share – basic

($0.03)

($0.07)

($0.97)

$0.28

Income (loss) from discontinued operations per share – basic

$0.00

($0.13)

$0.00

($0.34)

Income (loss) earnings per share – basic

($0.03)

($0.20)

($0.97)

($0.06)

 
Income (loss) from continuing operations per share – diluted

($0.03)

($0.07)

($0.97)

$0.28

Income (loss) from discontinued operations per share – diluted

$0.00

($0.13)

$0.00

($0.34)

Income (loss) earnings per share – diluted

($0.03)

($0.20)

($0.97)

($0.06)

 
Weighted average common shares outstanding:
Basic

166.4

174.6

167.6

176.9

Diluted

166.4

174.6

167.6

176.9

 

Three Months Ended September 30,

Nine Months Ended September 30,

2019

2018

2019

2018

 
(a) Amortization of software development and acquisition-related assets includes:
Amortization of capitalized software development costs

$20.1

$15.9

$59.3

$47.0

Amortization of acquisition-related intangible assets

9.2

9.6

27.2

29.0

$29.3

$25.5

$86.5

$76.0

 
(b) Interest expense and other, net are comprised of the following for the periods presented:
 
Non-cash charges to interest expense

$3.4

$3.2

$10.0

$9.5

Interest expense

6.7

9.4

19.3

25.4

Amortization of discounts and debt issuance costs

0.7

0.7

2.1

2.1

Other (income) loss, net

(0.8)

0.6

143.7

0.6

Total interest expense and other, net

$10.0

$13.9

$175.1

$37.6

Table 3
Allscripts Healthcare Solutions, Inc.
Condensed Consolidated Statements of Cash Flows
(In millions)
(Unaudited)
 

Three Months Ended September 30,

Nine Months Ended September 30,

2019

2018

2019

2018

Cash flows from operating activities:
Net income (loss)

($5.7)

($23.8)

($163.6)

$21.9

Less: Income(loss) from discontinued operations

0.0

(11.7)

0.0

(25.4)

Income (loss) from continuing operations

($5.7)

($12.1)

($163.6)

$47.3

Non-cash adjustments to net income (loss):
Depreciation and amortization

51.7

47.8

152.3

143.0

Operating right-to-use asset amortization

5.7

0.0

16.7

0.0

Stock-based compensation expense

7.8

8.6

29.6

25.8

Asset impairment charges

0.2

0.0

4.0

30.1

Impairment (recovery) of long-term investments

0.0

0.0

(1.0)

15.5

(Gain) loss on sale of businesses, net

0.0

0.0

0.0

(172.3)

Other, net

(1.3)

(3.4)

(1.0)

4.6

Total non-cash adjustments to net income (loss)

64.1

53.0

200.6

46.7

Cash impact of changes in operating assets and liabilities

(22.6)

(37.2)

26.9

(28.8)

Net cash provided by (used in) operating activities – continuing operations

35.8

3.7

63.9

65.2

Net cash provided by (used in) operating activities – discontinued operations

0.0

11.3

(30.0)

16.3

Net cash provide by (used in) operating activities

35.8

15.0

33.9

81.5

Cash flows from investing activities:
Capital expenditures

(4.1)

(7.9)

(13.5)

(21.9)

Capitalized software

(31.0)

(25.8)

(86.2)

(83.1)

Purchases of equity securities in partner entities, business
acquisitions, net of cash acquired and other investments

(17.7)

(5.6)

(30.6)

61.2

Net cash provided by (used in) investing activities – continuing
operations

(52.8)

(39.3)

(130.3)

(43.8)

Net cash provided by (used in) investing activities – discontinued operations

0.0

(173.5)

0.0

(189.5)

Net cash provided by (used in) investing activities

(52.8)

(212.8)

(130.3)

(233.3)

Cash flows from financing activities:
Repurchase of common stock

(37.1)

0.0

(102.2)

(101.9)

Repurchase of unsettled common stock

(9.3)

0.0

(9.3)

0.0

Proceeds from sale or issuance of common stock

0.0

1.1

0.0

1.3

Stock-based compensation-related payments, net

(0.1)

(0.2)

(6.8)

(8.8)

Credit facilities and capital lease payments, net

64.2

14.9

234.1

75.5

Other payments

(9.9)

0.0

(65.4)

(10.2)

Net cash provided by (used in) financing activities – continuing operations

7.8

15.8

50.4

(44.1)

Net cash provided by (used in) financing activities – discontinued operations

0.0

161.1

0.0

153.5

Net cash provided by (used in) financing activities

7.8

176.9

50.4

109.4

Effect of exchange rate changes on cash and cash equivalents

(0.2)

(0.1)

(0.1)

(0.3)

Net increase (decrease) in cash and cash equivalents

(9.4)

(21.0)

(46.1)

(42.7)

Cash and cash equivalents, beginning of period

148.1

140.8

184.8

162.5

Cash and cash equivalents, end of period

$138.7

$119.8

$138.7

$119.8

Less: Cash and cash equivalents included in current assets attributable to discontinued operations

0.0

(17.8)

0.0

(17.8)

Cash, cash equivalents and restricted cash, end of period, excluding discontinued operations

$138.7

$102.0

$138.7

$102.0

Table 4
Allscripts Healthcare Solutions, Inc.
Condensed Non-GAAP Financial Information
(In millions, except per share amounts)
(Unaudited)
 

Three Months Ended September 30, 2019

Three Months Ended September 30, 2018

GAAP

Non-GAAP

Adjustments (1)

Non-GAAP

GAAP

Non-GAAP

Adjustments (1)

Non-GAAP

 
Revenue

$444.2

$0.4

$444.6

$432.5

$7.3

$439.8

Gross profit

175.3

16.7

192.0

178.1

21.6

199.7

Total Operating Expenses

172.1

(24.2)

147.9

177.7

(27.9)

149.8

Income (loss) from operations

3.2

40.9

44.1

0.4

49.5

49.9

Income (loss) from continuing operations, net of tax, net of non-controlling interest

($5.7)

$34.1

$28.4

($12.1)

$40.7

$28.6

 
Income (loss) from continuing operations per share – diluted

($0.03)

$0.17

($0.07)

$0.16

 
Effective Tax Rate

12%

24%

13%

27%

 
Weighted average common shares outstanding – diluted

166.4

167.9

174.6

177.2

 
 

Nine Months Ended September 30, 2019

Nine Months Ended September 30, 2018

GAAP

Non-GAAP

Adjustments (1)

Non-GAAP

GAAP

Non-GAAP

Adjustments (1)

Non-GAAP

 
Revenue

$1,320.7

$1.5

$1,322.2

$1,307.7

$16.6

$1,324.3

Gross profit

533.5

41.4

574.9

536.5

71.5

608.0

Total Operating Expenses

522.9

(78.6)

444.3

603.0

(139.3)

463.7

Income (loss) from operations

10.6

120.0

130.6

(66.5)

210.8

144.3

Income (loss) from continuing operations, net of tax, net of non-controlling interest

($163.2)

$247.2

$84.0

$50.8

$38.6

$89.4

 
Income (loss) from continuing operations per share – diluted

($0.97)

$0.50

$0.28

$0.50

 
Effective Tax Rate

0%

24%

11%

27%

 
Weighted average common shares outstanding – diluted

167.6

169.1

176.9

179.3

 
(1) Please see table 6 for detail on Non-GAAP adjustments.
Table 5
Allscripts Healthcare Solutions, Inc.
Non-GAAP Financial Information – Adjusted EBITDA
(In millions, except percentages)
(Unaudited)
 

Three Months Ended September 30,

Nine Months Ended September 30,

2019

2018

2019

2018

Net income (loss) from continuing operations, as reported

($5.7)

($12.1)

($163.6)

$47.3

Plus:
Interest expense and other, net (a)

5.9

10.0

18.0

26.0

Depreciation and amortization

51.7

47.8

152.3

143.0

Equity in net (income) loss of unconsolidated investments

(0.3)

0.3

(0.5)

(0.4)

Tax provision/(benefit)

(0.8)

(1.8)

0.6

5.8

EBITDA

$50.8

$44.2

$6.8

$221.7

Plus:
Acquisition-related deferred revenue adjustments

0.4

9.5

1.5

23.4

Stock-based compensation expense

8.5

10.0

32.5

29.9

Transaction, legal and other costs

14.1

14.0

177.5

78.9

Asset impairment charges

0.2

0.0

4.0

30.1

(Recovery) impairment on long-term investments

0.0

0.0

(1.0)

15.5

(Gain) loss on sale of business, net

0.0

0.0

0.0

(172.3)

Adjusted EBITDA

$74.0

$77.7

$221.3

$227.2

 
Adjusted EBITDA margin (b)

17%

18%

17%

17%

 
 
(a) Interest expense and other, net has been adjusted from the amounts presented in the statements of operations in order to remove the amortization of the fair value of the cash conversion option embedded in the 1.25% Cash Convertible Notes and deferred debt issuance costs from interest expense since such amortization is also included in depreciation and amortization.
 
(b) Adjusted EBITDA margin is calculated by dividing adjusted EBITDA by non-GAAP revenue.
Table 6
Allscripts Healthcare Solutions, Inc.
Non-GAAP Financial Information – Non-GAAP Adjustments
(In millions, except percentages)
(Unaudited)
 
 

Three Months Ended September 30,

Nine Months Ended September 30,

2019

2018

2019

2018

 
Income (loss) from continuing operations, net of tax and net of non-controlling interest

($5.7)

($12.1)

($163.2)

$50.8

Acquisition-related deferred revenue adjustments

0.4

9.5

1.5

23.4

Revenue

0.4

7.3

1.5

16.6

Gross Profit

0.4

9.5

1.5

23.4

Income (loss) from operations

0.4

9.5

1.5

23.4

Acquisition-related amortization

16.1

16.1

47.6

48.6

Gross Profit

9.2

9.5

27.2

29.0

Income (loss) from operations

16.1

16.1

47.6

48.6

Stock-based compensation expense

8.5

10.0

32.5

29.9

Gross Profit

1.1

1.5

4.5

5.1

Income (loss) from operations

8.5

10.0

32.5

29.9

Asset impairment charges

0.2

0.0

4.0

30.1

Income (loss) from operations

0.2

0.0

4.0

30.1

Transaction, legal and other costs

15.6

14.0

179.3

78.8

Gross Profit

6.0

1.1

8.2

14.0

Income (loss) from operations

15.7

14.0

34.4

78.8

Income (loss) from continuing operations before income taxes

15.6

14.0

179.3

78.8

Non-cash charges to interest expense and other

3.4

3.8

10.0

11.0

(Recovery) impairment on long-term investments

0.0

0.0

(1.0)

15.5

(Gain) loss on sale of business, net

0.0

0.0

0.0

(172.3)

Equity in net (income) loss of unconsolidated investments

(0.3)

0.3

(0.5)

(0.4)

Tax rate alignment

(9.8)

(12.5)

(25.9)

(26.0)

Net (income) loss attributable to non-controlling interest

0.0

(0.5)

(0.3)

0.0

Non-GAAP income (loss) attributable to Allscripts Healthcare Solutions, Inc.

$28.4

$28.6

$84.0

$89.4

 
Non-GAAP effective tax rate

24%

27%

24%

27%

 
Weighted average shares outstanding – diluted

167.9

177.2

169.1

179.3

Table 7
Allscripts Healthcare Solutions, Inc.
Non-GAAP Financial Information – Free Cash Flow
(In millions)
(Unaudited)
 

Three Months Ended September 30,

Nine Months Ended September 30,

2019

2018

2019

2018

Net cash provided by (used in) operating activities – continuing operations

$35.8

$3.7

$63.9

$65.2

Net cash provided by (used in) operating activities – discontinued operations

0.0

11.3

(30.0)

16.3

Net cash provided by (used in) operating activities

35.8

15.0

33.9

81.5

Cash flows from investing activities:
Capital expenditures

(4.1)

(7.9)

(13.5)

(21.9)

Capitalized software

(31.0)

(25.8)

(86.2)

(83.1)

Cash flows from investing activities – discontinued operations

 

0.0

(8.7)

0.0

(22.9)

Free cash flow

$0.7

($27.4)

($65.8)

($46.4)

Contacts

For more information contact:

Investors:

Stephen Shulstein

312-386-6735

[email protected]

Media:
Tom Lynch

312-386-6765

[email protected]

Read full story here

error: Content is protected !!